Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Bladder Cancer”

24 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 24 results

Testing effectiveness (Phase 2)Looking for participantsNCT07296705
What this trial is testing

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

Who this might be right for
Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital 25
Early research (Phase 1)Study completedNCT03650348
What this trial is testing

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more
Pieris Pharmaceuticals, Inc. 41
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05356351
What this trial is testing

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

Who this might be right for
Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
Tianjin Medical University Cancer Institute and Hospital 30
Early research (Phase 1)Looking for participantsNCT06253871
What this trial is testing

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Who this might be right for
HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more
Iambic Therapeutics, Inc 243
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Not applicableLooking for participantsNCT07038928
What this trial is testing

TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Who this might be right for
Bladder Cancer
AstraZeneca 600
Testing effectiveness (Phase 2)Ended earlyNCT00447226
What this trial is testing

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

Who this might be right for
Cancer
GlaxoSmithKline 32
Early research (Phase 1)Looking for participantsNCT03740256
What this trial is testing

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

Who this might be right for
Bladder CancerHead and Neck Squamous Cell CarcinomaCancer of the Salivary Gland+7 more
Baylor College of Medicine 45
Early research (Phase 1)Active Not RecruitingNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 120
Early research (Phase 1)Study completedNCT03330561
What this trial is testing

PRS-343 in HER2-Positive Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more
Pieris Pharmaceuticals, Inc. 85
Early research (Phase 1)Looking for participantsNCT06257264
What this trial is testing

Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Who this might be right for
Breast CancerSmall Cell Lung CancerOvarian Cancer+9 more
BeiGene 258
Testing effectiveness (Phase 2)Active Not RecruitingNCT04561362
What this trial is testing

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Who this might be right for
Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative Neoplasms+5 more
BicycleTx Limited 329
Not applicableLooking for participantsNCT07124000
What this trial is testing

DESTINY-PANTUMOUR04

Who this might be right for
Adenocarcinoma (NOS)Anal CancerBladder Cancer+24 more
AstraZeneca 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07151560
What this trial is testing

Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial

Who this might be right for
Urology
Renmin Hospital of Wuhan University 60
Testing effectiveness (Phase 2)Looking for participantsNCT05969860
What this trial is testing

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Who this might be right for
Advanced Anal CarcinomaAdvanced Biliary Tract CarcinomaAdvanced Bladder Carcinoma+40 more
Mayo Clinic 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05996952
What this trial is testing

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer
West China Hospital 77
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07279597
What this trial is testing

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

Who this might be right for
Muscle-invasive Bladder Urothelial Carcinoma
Tongji Hospital 45
Early research (Phase 1)Ended earlyNCT04209465
What this trial is testing

BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Who this might be right for
Solid Tumor
Black Diamond Therapeutics, Inc. 91
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Load More Results